APO Research
Talk to an analyst

APO RESEARCH · REPORT

GM1 Gangliosidosis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GM1 Gangliosidosis Treatment Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchGM1 Gangliosidosis Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal GM1 Gangliosidosis Treatment Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal GM1 Gangliosidosis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GM1 Gangliosidosis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal GM1 Gangliosidosis Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global GM1 Gangliosidosis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GM1 Gangliosidosis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GM1 Gangliosidosis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GM1 Gangliosidosis Treatment market include Axovant Gene Therapies Ltd and Passage Bio and Lysogene among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GM1 Gangliosidosis Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GM1 Gangliosidosis Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GM1 Gangliosidosis Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GM1 Gangliosidosis Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

GM1 Gangliosidosis Treatment Segment by Company

Axovant Gene Therapies Ltd

Passage Bio and Lysogene

GM1 Gangliosidosis Treatment Segment by Type

AXO-AAV-GM1

LYS-GM101

PBGM01

GM1 Gangliosidosis Treatment Segment by Application

Type 3 GM1 Gangliosidosis

Type 2 GM1 Gangliosidosis

Type 1 GM1 Gangliosidosis

GM1 Gangliosidosis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global GM1 Gangliosidosis Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GM1 Gangliosidosis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GM1 Gangliosidosis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze GM1 Gangliosidosis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GM1 Gangliosidosis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GM1 Gangliosidosis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GM1 Gangliosidosis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GM1 Gangliosidosis Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GM1 Gangliosidosis Treatment industry.

Chapter 3: Detailed analysis of GM1 Gangliosidosis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GM1 Gangliosidosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GM1 Gangliosidosis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GM1 Gangliosidosis Treatment Industry Trends Table 2. GM1 Gangliosidosis Treatment Industry Drivers Table 3. GM1 Gangliosidosis Treatment Industry Opportunities and Challenges Table 4. GM1 Gangliosidosis Treatment Industry Restraints Table 5. Global GM1 Gangliosidosis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GM1 Gangliosidosis Treatment Revenue Share by Company (2021-2026) Table 7. Global GM1 Gangliosidosis Treatment Sales Volume by Company (K Units) & (2021-2026) Table 8. Global GM1 Gangliosidosis Treatment Sales Volume Share by Company (2021-2026) Table 9. Global GM1 Gangliosidosis Treatment Average Price (US$/Unit) of Company (2021-2026) Table 10. Global GM1 Gangliosidosis Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global GM1 Gangliosidosis Treatment Key Company Manufacturing Base & Headquarters Table 12. Global GM1 Gangliosidosis Treatment Company, Product Type & Application Table 13. Global GM1 Gangliosidosis Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GM1 Gangliosidosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AXO-AAV-GM1 Table 18. Significant Companies of LYS-GM101 Table 19. Significant Companies of PBGM01 Table 20. Global GM1 Gangliosidosis Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global GM1 Gangliosidosis Treatment Sales Volume by Type (2021-2026) & (K Units) Table 22. Global GM1 Gangliosidosis Treatment Sales Volume by Type (2027-2032) & (K Units) Table 23. Global GM1 Gangliosidosis Treatment Sales Volume Share by Type (2021-2026) Table 24. Global GM1 Gangliosidosis Treatment Sales Volume Share by Type (2027-2032) Table 25. Global GM1 Gangliosidosis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global GM1 Gangliosidosis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global GM1 Gangliosidosis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global GM1 Gangliosidosis Treatment Sales Value Share by Type (2021-2026) Table 29. Global GM1 Gangliosidosis Treatment Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Type 3 GM1 Gangliosidosis Table 31. Significant Companies of Type 2 GM1 Gangliosidosis Table 32. Significant Companies of Type 1 GM1 Gangliosidosis Table 33. Global GM1 Gangliosidosis Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global GM1 Gangliosidosis Treatment Sales Volume by Application (2021-2026) & (K Units) Table 35. Global GM1 Gangliosidosis Treatment Sales Volume by Application (2027-2032) & (K Units) Table 36. Global GM1 Gangliosidosis Treatment Sales Volume Share by Application (2021-2026) Table 37. Global GM1 Gangliosidosis Treatment Sales Volume Share by Application (2027-2032) Table 38. Global GM1 Gangliosidosis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global GM1 Gangliosidosis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global GM1 Gangliosidosis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global GM1 Gangliosidosis Treatment Sales Value Share by Application (2021-2026) Table 42. Global GM1 Gangliosidosis Treatment Sales Value Share by Application (2027-2032) Table 43. Global GM1 Gangliosidosis Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global GM1 Gangliosidosis Treatment Sales by Region (2021-2026) & (K Units) Table 45. Global GM1 Gangliosidosis Treatment Sales Market Share by Region (2021-2026) Table 46. Global GM1 Gangliosidosis Treatment Sales by Region (2027-2032) & (K Units) Table 47. Global GM1 Gangliosidosis Treatment Sales Market Share by Region (2027-2032) Table 48. Global GM1 Gangliosidosis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global GM1 Gangliosidosis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global GM1 Gangliosidosis Treatment Sales Value Share by Region (2021-2026) Table 51. Global GM1 Gangliosidosis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global GM1 Gangliosidosis Treatment Sales Value Share by Region (2027-2032) Table 53. Global GM1 Gangliosidosis Treatment Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global GM1 Gangliosidosis Treatment Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global GM1 Gangliosidosis Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global GM1 Gangliosidosis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global GM1 Gangliosidosis Treatment Sales by Country (2021-2026) & (K Units) Table 58. Global GM1 Gangliosidosis Treatment Sales Market Share by Country (2021-2026) Table 59. Global GM1 Gangliosidosis Treatment Sales by Country (2027-2032) & (K Units) Table 60. Global GM1 Gangliosidosis Treatment Sales Market Share by Country (2027-2032) Table 61. Global GM1 Gangliosidosis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global GM1 Gangliosidosis Treatment Sales Value Market Share by Country (2021-2026) Table 63. Global GM1 Gangliosidosis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global GM1 Gangliosidosis Treatment Sales Value Market Share by Country (2027-2032) Table 65. Axovant Gene Therapies Ltd Company Information Table 66. Axovant Gene Therapies Ltd Business Overview Table 67. Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Product Portfolio Table 69. Axovant Gene Therapies Ltd Recent Development Table 70. Passage Bio and Lysogene Company Information Table 71. Passage Bio and Lysogene Business Overview Table 72. Passage Bio and Lysogene GM1 Gangliosidosis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Passage Bio and Lysogene GM1 Gangliosidosis Treatment Product Portfolio Table 74. Passage Bio and Lysogene Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. GM1 Gangliosidosis Treatment Distributors List Table 78. GM1 Gangliosidosis Treatment Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. GM1 Gangliosidosis Treatment Product Image Figure 2. Global GM1 Gangliosidosis Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global GM1 Gangliosidosis Treatment Sales (2021-2032) & (K Units) Figure 5. Global GM1 Gangliosidosis Treatment Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global GM1 Gangliosidosis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AXO-AAV-GM1 Image Figure 10. LYS-GM101 Image Figure 11. PBGM01 Image Figure 12. Global GM1 Gangliosidosis Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global GM1 Gangliosidosis Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global GM1 Gangliosidosis Treatment Sales Volume Share by Type (2021-2032) Figure 15. Global GM1 Gangliosidosis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global GM1 Gangliosidosis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global GM1 Gangliosidosis Treatment Sales Value Share by Type (2021-2032) Figure 18. Type 3 GM1 Gangliosidosis Image Figure 19. Type 2 GM1 Gangliosidosis Image Figure 20. Type 1 GM1 Gangliosidosis Image Figure 21. Global GM1 Gangliosidosis Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global GM1 Gangliosidosis Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global GM1 Gangliosidosis Treatment Sales Volume Share by Application (2021-2032) Figure 24. Global GM1 Gangliosidosis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global GM1 Gangliosidosis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global GM1 Gangliosidosis Treatment Sales Value Share by Application (2021-2032) Figure 27. Global GM1 Gangliosidosis Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global GM1 Gangliosidosis Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global GM1 Gangliosidosis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global GM1 Gangliosidosis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. North America GM1 Gangliosidosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. Europe GM1 Gangliosidosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific GM1 Gangliosidosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. South America GM1 Gangliosidosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa GM1 Gangliosidosis Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa GM1 Gangliosidosis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. GM1 Gangliosidosis Treatment Value Chain Figure 126. Manufacturing Cost Structure Figure 127. GM1 Gangliosidosis Treatment Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • AXO-AAV-GM1
  • LYS-GM101
  • PBGM01
Applications
  • Type 3 GM1 Gangliosidosis
  • Type 2 GM1 Gangliosidosis
  • Type 1 GM1 Gangliosidosis
Companies covered
  • Axovant Gene Therapies Ltd
  • Passage Bio and Lysogene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  4. 1.2.2 Global GM1 Gangliosidosis Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global GM1 Gangliosidosis Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GM1 Gangliosidosis Treatment Market Dynamics
  1. 2.1 GM1 Gangliosidosis Treatment Industry Trends
  2. 2.2 GM1 Gangliosidosis Treatment Industry Drivers
  3. 2.3 GM1 Gangliosidosis Treatment Industry Opportunities and Challenges
  4. 2.4 GM1 Gangliosidosis Treatment Industry Restraints
3 GM1 Gangliosidosis Treatment Market by Company
  1. 3.1 Global GM1 Gangliosidosis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global GM1 Gangliosidosis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global GM1 Gangliosidosis Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global GM1 Gangliosidosis Treatment Average Price by Company (2021-2026)
  5. 3.5 Global GM1 Gangliosidosis Treatment Company Ranking (2024-2026)
  6. 3.6 Global GM1 Gangliosidosis Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global GM1 Gangliosidosis Treatment Company Product Type and Application
  8. 3.8 Global GM1 Gangliosidosis Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GM1 Gangliosidosis Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GM1 Gangliosidosis Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GM1 Gangliosidosis Treatment Market by Type
  1. 4.1 GM1 Gangliosidosis Treatment Type Introduction
  2. 4.1.1 AXO-AAV-GM1
  3. 4.1.2 LYS-GM101
  4. 4.1.3 PBGM01
  5. 4.2 Global GM1 Gangliosidosis Treatment Sales Volume by Type
  6. 4.2.1 Global GM1 Gangliosidosis Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global GM1 Gangliosidosis Treatment Sales Volume by Type (2021-2032)
  8. 4.2.3 Global GM1 Gangliosidosis Treatment Sales Volume Share by Type (2021-2032)
  9. 4.3 Global GM1 Gangliosidosis Treatment Sales Value by Type
  10. 4.3.1 Global GM1 Gangliosidosis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global GM1 Gangliosidosis Treatment Sales Value by Type (2021-2032)
  12. 4.3.3 Global GM1 Gangliosidosis Treatment Sales Value Share by Type (2021-2032)
5 GM1 Gangliosidosis Treatment Market by Application
  1. 5.1 GM1 Gangliosidosis Treatment Application Introduction
  2. 5.1.1 Type 3 GM1 Gangliosidosis
  3. 5.1.2 Type 2 GM1 Gangliosidosis
  4. 5.1.3 Type 1 GM1 Gangliosidosis
  5. 5.2 Global GM1 Gangliosidosis Treatment Sales Volume by Application
  6. 5.2.1 Global GM1 Gangliosidosis Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GM1 Gangliosidosis Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global GM1 Gangliosidosis Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global GM1 Gangliosidosis Treatment Sales Value by Application
  10. 5.3.1 Global GM1 Gangliosidosis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GM1 Gangliosidosis Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global GM1 Gangliosidosis Treatment Sales Value Share by Application (2021-2032)
6 GM1 Gangliosidosis Treatment Regional Sales and Value Analysis
  1. 6.1 Global GM1 Gangliosidosis Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GM1 Gangliosidosis Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global GM1 Gangliosidosis Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global GM1 Gangliosidosis Treatment Sales by Region (2027-2032)
  5. 6.3 Global GM1 Gangliosidosis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GM1 Gangliosidosis Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global GM1 Gangliosidosis Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global GM1 Gangliosidosis Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global GM1 Gangliosidosis Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  12. 6.6.2 North America GM1 Gangliosidosis Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe GM1 Gangliosidosis Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GM1 Gangliosidosis Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  21. 6.9.2 South America GM1 Gangliosidosis Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GM1 Gangliosidosis Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GM1 Gangliosidosis Treatment Sales Value Share by Country, 2025 VS 2032
7 GM1 Gangliosidosis Treatment Country-level Sales and Value Analysis
  1. 7.1 Global GM1 Gangliosidosis Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GM1 Gangliosidosis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GM1 Gangliosidosis Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global GM1 Gangliosidosis Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global GM1 Gangliosidosis Treatment Sales by Country (2027-2032)
  6. 7.4 Global GM1 Gangliosidosis Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global GM1 Gangliosidosis Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global GM1 Gangliosidosis Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GM1 Gangliosidosis Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GM1 Gangliosidosis Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GM1 Gangliosidosis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Axovant Gene Therapies Ltd
  2. 8.1.1 Axovant Gene Therapies Ltd Company Information
  3. 8.1.2 Axovant Gene Therapies Ltd Business Overview
  4. 8.1.3 Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Axovant Gene Therapies Ltd GM1 Gangliosidosis Treatment Product Portfolio
  6. 8.1.5 Axovant Gene Therapies Ltd Recent Developments
  7. 8.2 Passage Bio and Lysogene
  8. 8.2.1 Passage Bio and Lysogene Company Information
  9. 8.2.2 Passage Bio and Lysogene Business Overview
  10. 8.2.3 Passage Bio and Lysogene GM1 Gangliosidosis Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Passage Bio and Lysogene GM1 Gangliosidosis Treatment Product Portfolio
  12. 8.2.5 Passage Bio and Lysogene Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GM1 Gangliosidosis Treatment Value Chain Analysis
  2. 9.1.1 GM1 Gangliosidosis Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GM1 Gangliosidosis Treatment Sales Mode & Process
  6. 9.2 GM1 Gangliosidosis Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GM1 Gangliosidosis Treatment Distributors
  9. 9.2.3 GM1 Gangliosidosis Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst